Evidence map›Paper›PMID 40829202›Full record

ArticleThe Journal of pharmacology and experimental therapeutics2025

Coated nanoparticles enhance immune efficacy of Helicobacter pylori outer membrane vesicles by activating Th1/Th2/Th17 responses.

Songling Ye, Jin Liu, Shiyuan Huang, Luo Chen, Xinyi Zeng, Jingjing Zhao, Suqing Zhao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of pharmacology and experimental therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Songling YeDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People's Republic of China.
Jin LiuDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People's Republic of China.
Shiyuan HuangDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People's Republic of China.
Luo ChenDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People's Republic of China.
Xinyi ZengDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People's Republic of China.
Jingjing ZhaoDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People's Republic of China. Electronic address: jjzhao@gdut.edu.cn.
Suqing ZhaoDepartment of Pharmaceutical Engineering, School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, People's Republic of China. Electronic address: sqzhao@gdut.edu.cn.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotic resistance has emerged as a pressing global public health crisis. The development of a safe and efficient Helicobacter pylori vaccine has become an important measure to eradicate Hpylori infection. Outer membrane vesicles (OMVs) secreted by Gram-negative bacteria are immunogenic and have received increasing attention in the development of vaccines against bacterial infections. In this study, Hpylori was used as a model pathogen, Hpylori outer membrane vesicle (HM) as an antigen, and dendritic mesoporous organosilica nanoparticles (DMON) as a carrier to load lipopolysaccharide (LPS) as an adjuvant to obtain a stable LPS@DMON@HM vaccine. The nanovaccine markedly enhanced the phagocytosis of macrophages and the secretion of IL-4, IFN-gamma, and IL-17A in vitro. In vivo, LPS@DMON@HM can significantly increase the specific antibody titer, and the serum-specific IgG antibody titer after vaccine immunization can reach 1:12,800, which is 16 times that of free HM immunization. Further studies indicated that the levels of Th1, Th2, and Th17 cytokines in spleen cells were induced to show a marked elevation. The results showed that LPS@DMON@HM had stronger immunogenicity and induced higher levels of humoral immunity, mucosal immunity, and Th1/Th2/Th17 cellular immune responses compared with free HM. The vaccine exhibited no toxicity at the tested doses. This study establishes a mechanistic foundation for developing next-generation Hpylori vaccines with optimized safety-efficacy profiles and simultaneously offers a reference for the development of vaccines against other Gram-negative pathogens. SIGNIFICANCE STATEMENT: Infection with Helicobacter pylori is closely associated with a wide range of gastrointestinal diseases; however, antibiotic resistance has been significantly undermining its therapeutic efficacy. The LPS@DMON@HM nanovaccine developed in this study can induce high levels of anti-Hpylori IgG after immunization of mice and can also induce mucosal immunity and Th1/Th2/Th17 mixed immune responses. It is anticipated to be further investigated as a nonantibiotic therapeutic option for Hpylori infection.

Indexed as

Bacterial Outer MembraneBacterial VaccinesHelicobacter pyloriNanoparticlesTh17 CellsTh1 CellsTh2 CellsAnimalsCytokinesFemaleLipopolysaccharidesMiceMice, Inbred BALB CBacterial VaccinesCytokinesLipopolysaccharidesDendritic mesoporous organosilicaHelicobacter pyloriImmunityNanovaccineOuter membrane vesicles

Identifiers

PMID40829202
PMCPMC12597630

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.